Pharmaceutical salt of BM635 with improved bioavailability

About the Center for Drug Evaluation and Research>The Biopharmaceutics Classification System (BCS) Guidance [WWW Document], n.d. URL http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219.htm (accessed 2.19.16). Apperley, 2002, Response to imatinib mesylate in patients with chronic Myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor Beta, N. Engl. J. Med., 347, 481, 10.1056/NEJMoa020150 Black, 2007, Structure, solubility, screening, and synthesis of molecular salts, J. Pharm. Sci., 96, 1053, 10.1002/jps.20927 Di, 2012, Bridging solubility between drug discovery and development, Drug Discov. Today, 17, 486, 10.1016/j.drudis.2011.11.007 Elder, 1992 Elder, 2010, The utility of sulfonate salts in drug development, J. Pharm. Sci., 99, 2948, 10.1002/jps.22058 Kwong, 2015, Advancing drug discovery: a pharmaceutics perspective, J. Pharm. Sci., 104, 865, 10.1002/jps.24294 La Rosa, 2012, MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212, Antimicrob. Agents Chemother., 56, 324, 10.1128/AAC.05270-11 Li, 2005, Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH, Pharm. Res., 22, 628, 10.1007/s11095-005-2504-z Mannava, 2016, Enhanced bioavailability in the oxalate salt of the anti-tuberculosis drug ethionamide, Cryst. Growth Des., 16, 1591, 10.1021/acs.cgd.5b01700 Ochi, 2013, Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility, Pharm. Res., 30, 377, 10.1007/s11095-012-0878-2 O'Connor, 2001, Preparation and characterisation of a range of diclofenac salts, Int. J. Pharm., 226, 163, 10.1016/S0378-5173(01)00800-6 Paik, 2010, A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies, Cancer Chemother. Pharmacol., 66, 1079, 10.1007/s00280-010-1265-5 Poce, 2013, Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection, PLoS One, 8, 10.1371/journal.pone.0056980 Sanphui, 2013, Salt and Cocrystals of sildenafil with Dicarboxylic acids: solubility and pharmacokinetic advantage of the Glutarate salt, Mol. Pharm., 10, 4687, 10.1021/mp400516b Semin, 2003, Salt screening and selection Surov, 2015, Pharmaceutical salts of ciprofloxacin with dicarboxylic acids, Eur. J. Pharm. Sci., 77, 112, 10.1016/j.ejps.2015.06.004 Teasdale, 2009, Org. Process Res. Dev., 13, 429, 10.1021/op800192a Verbeeck, 2006, Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy, Eur. J. Pharm. Sci., 28, 1, 10.1016/j.ejps.2005.12.001 Williams, 2013, Strategies to address low drug solubility in discovery and development, Pharmacol. Rev., 65, 315, 10.1124/pr.112.005660